{"status": "Ok", "redirect_url": "https://investors.pfizer.com/Investors/news-events/News/news-details/2026/U-S--FDA-Grants-Priority-Review-to-sBLA-for-PADCEV--Keytruda-as-Perioperative-Treatment-for-Muscle-Invasive-Bladder-Cancer-Regardless-of-Cisplatin-Eligibility-2026--aYF8zy9gB/default.aspx", "message": "News view counter 671513 successfully enlarged"}